Dr. Mo Yang is a senior health economics and outcomes research (HEOR) analyst at Ariad Pharmaceutical Inc. in Cambridge, MA. Before this, she was a principal research associate at Allergan Inc. in Irvine, CA. She earned her Master and Ph.D in Pharmacy Administration from the Department of Pharmaceutical Health Outcomes and Policy, College of Pharmacy, University of Houston.
She is a co-founder, serving as a board of Director and Secretary at the International Association of Medical and Pharmacy Professionals. She also serves on Editorial board as well as Scientific Advisory board for quite a few peer-reviewed journals. She is experienced in both prospective and retrospective research study design, economics and cost analyses, and systematic review and meta-analysis. She has almost 20 peer-reviewed publications to date.
Prevention and intervention of tobacco use and obesity; Prophylactic treatment for chronic migraine patient; Pharmacotherapy treatment among patients diagnosed with cancer; Development and validation of patient-reported outcomes (PRO) instruments; Health economics and cost analysis including Cost-effectiveness analysis; Cost-utility analysis using Markov model; Conducting systematic literature review and meta-analysis; Prospective and retrospective research study design and data analysis.